Susquehanna Fundamental Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
Other funds holding RETA
CI
Susquehanna Fundamental Investments's RETA Position: Q4 2021 in Review
Susquehanna Fundamental Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 3,680 shares — an estimated $370K sold.
Susquehanna Fundamental Investments first reported a position in RETA in Q2 2020 and held it in 5 quarters. The position peaked at $3.38M in Q4 2020. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.
- Susquehanna Fundamental Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
- Susquehanna Fundamental Investments sold 3,680 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $370K.
- Susquehanna Fundamental Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 5 quarters.
- Susquehanna Fundamental Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.38M in Q4 2020.
- 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.
Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.